Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

ESTUDIOS


21 marzo 2014

EUROPEAN HEART JOURNAL. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study

Roberto Diletti, Antonios Karanasos, Takashi Muramatsu, Shimpei Nakatani, Nicolas M. Van Mieghem, Yoshinobu Onuma, Sjoerd T. Nauta, Yuki Ishibashi, Mattie J. Lenzen, Jurgen Ligthart, Carl Schultz, Evelyn Regar, Peter P. de Jaegere, Patrick W. Serruys, Felix Zijlstra and Robert Jan van Geuns*

Aims: We evaluated the feasibility and the acute performance of the everolimus-eluting bioresorbable vascular scaffolds (BVS) for the treatment of patients presenting with ST-segment elevation myocardial infarction (STEMI).

21 marzo 2014

EUROPEAN HEART JOURNAL. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study ‘Prague 19’

Viktor Kočka1, Martin Malý2, Petr Toušek1, Tomas Buděšínský1, Libor Lisa1, Petko Prodanov1, Jiri Jarkovský3 and Petr Widimský1,*

Aims: Bioresorbable vascular scaffolds (BVSs) have been studied in chronic coronary artery disease, but not in acute ST-segment elevation myocardial infarction (STEMI). This prospective multicentre study analysed the feasibility and safety of BVS implantation during primary percutaneous coronary intervention (p-PCI) in STEMI.

04 febrero 2014

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Angiography. Angiographic Validation of the American College of Cardiology Foundation–The Society of Thoracic Surgeons Collaboration on the Comparative Effectiveness of Revascularization Strategies Study

Anjan K. Chakrabarti, MD, MPH, Maria V. Grau-Sepulveda, MD, MPH, Sean O’Brien, PhD, Cassandra Abueg, MPH, Angelo Ponirakis, PhD, Elizabeth Delong, PhD, Eric Peterson, MD, Lloyd W. Klein, MD, Kirk N. Garratt, MSc, MD, William S. Weintraub, MD and C. Michael Gibson, MS, MD

Background: The goal of this study was to compare angiographic interpretation of coronary arteriograms by sites in community practice versus those made by a centralized angiographic core laboratory.

01 febrero 2014

JACC: CARDIOVASCULAR INTERVENTIONS. A Prospective, Multicenter, Randomized Trial of Paclitaxel-Coated Balloon Versus Paclitaxel-Eluting Stent for the Treatment of Drug-Eluting Stent In-Stent Restenosis. Results From the PEPCAD China ISR Trial

Objectives: The intention of the PEPCAD China ISR (A Prospective, Multicenter, Randomized Trial of Paclitaxel-Coated versus Paclitaxel-Eluting Stent for the Treatment of Drug-Eluting Stent In-Stent Restenosis) was to demonstrate the efficacy of paclitaxel-coated balloon (PCB) angioplasty in a non-European patient population with coronary drug-eluting stent in-stent restenosis (DES-ISR).

01 febrero 2014

JACC. Variations in Coronary Artery Disease Secondary Prevention Prescriptions Among Outpatient Cardiology Practices

Thomas M. Maddox, MD, MSc∗; Paul S. Chan, MD, MSc§; John A. Spertus, MD, MPH§; Fengming Tang, MS§; Phil Jones, MS§; P. Michael Ho, MD, PhD∗; Steven M. Bradley, MD, MPH∗; Thomas T. Tsai, MD, MS∗; Deepak L. Bhatt, MD, MPH¶; Pamela N. Peterson, MD, MSPH†

Objectives: This study assessed practice variations in secondary prevention medication prescriptions among coronary artery disease (CAD) patients treated in outpatient practices participating in the National Cardiovascular Data Registry (NCDR) Practice Innovation and Clinical Excellence (PINNACLE) registry.

15 marzo 2014

THE AMERICAN JOURNAL OF CARDIOLOGY. Risk Factors for Progression of Functional Tricuspid Regurgitation

Avinoam Shiran, MD, Riham Najjar, BSc, Salim Adawi, MD, Doron Aronson, MD

The aim of this study was to determine the risk factors for tricuspid regurgitation (TR) progression in a contemporary population of patients referred for echocardiography. In a case-control study, we compared 100 consecutive patients with TR progression on serial echocardiograms (trivial or mild TR on the first echocardiogram and moderate or severe functional TR on a follow-up echocardiogram) with 100 patients matched for age and gender, having mild TR at baseline and no TR progression. Mean age was 72 ± 10 years, 55% were males, and time to TR progression was 5.3 ± 2.9 years. Less than 10% had rheumatic heart disease. Left ventricular ejection fraction was preserved (≥50%) in 85% of the TR progression group and in 74% of the control group (p = 0.06). Pulmonary artery systolic pressure increased from 41 ± 16 to 56 ± 18 mm Hg in the TR progression group and decreased from 44 ± 13 to 41 ± 11 mm Hg in the control group (p <0.0001). Independent risk factors for TR progression were pulmonary artery systolic pressure change during follow-up (odds ratio per 1 mm Hg 1.14, 95% confidence interval 1.06 to 1.23, p <0.0001), permanent atrial fibrillation (odds ratio 14.3, 95% confidence interval 4.6 to 44.2, p <0.0001), and coronary artery disease (odds ratio 5.7, 95% confidence interval 1.4 to 22.8, p = 0.015). All-cause mortality at 3 years was 20% for patients without TR progression, 42% for moderate TR, and 63% for severe TR, p <0.0001. Progression-to-severe TR independently predicted subsequent mortality. In conclusion, in patients with low prevalence of rheumatic heart disease and preserved left ventricular ejection fraction, pulmonary artery systolic pressure increase and permanent atrial fibrillation were the most powerful risk factors for TR progression. Progression-to-severe TR was an independent predictor of subsequent mortality.

01 marzo 2013

AMERICAN HEART JOURNAL. Comparison of costs between transradial and transfemoral percutaneous coronary intervention: A cohort analysis from the Premier research database

David M. Safley, MD, Amit P. Amin, MD, MSc, John A. House, MS, Dmitri Baklanov, MD, Rebecca Mills, MSM, Helmut Giersiefen, PhD, Andreas Bremer, PhD, Steven P. Marso, MD

Background: Transradial intervention (TRI) for percutaneous coronary intervention (PCI) is associated with shorter length of stay, fewer bleeding complications, and higher patient satisfaction. Less is known about the economic implications of TRI in contemporary practice.

01 marzo 2013

AMERICAN HEART JOURNAL. TransRadial Education And Therapeutics (TREAT): Shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention

Connie N. Hess, MD, Sunil V. Rao, MD, David F. Kong, MD, Julie M. Miller, MD, Kevin J. Anstrom, PhD, Olivier F. Bertrand, MD, Jean-Philippe Collet, MD, Mark B. Effron, MD, Benjamin C. Eloff, PhD, Emmanuel O. Fadiran, PhD, Andrew Farb, MD, Ian C. Gilchrist, MD, David R. Holmes, MD, Alice K. Jacobs, MD, Prashant Kaul, MD, L. Kristin Newby, MD, MHS, David R. Rutledge, PharmD, Dale R. Tavris, MD, MPH, Thomas T. Tsai, MD, MSc, Roseann M. White, MA, Eric D. Peterson, MD, MPH, Mitchell W. Krucoff, MD, FACC, FCCP

Percutaneous coronary intervention (PCI) is an integral part of the treatment of coronary artery disease. The most common complication of PCI, bleeding, typically occurs at the vascular access site and is associated with short-term and long-term morbidity and mortality. Periprocedural bleeding also represents the primary safety concern of concomitant antithrombotic therapies essential for PCI success. Use of radial access for PCI reduces procedural bleeding and hence may change the risk profile and net clinical benefit of these drugs. This new drug-device safety interaction creates opportunities to advance the safe and effective use of antithrombotic agents during PCI. In June 2010 and March 2011, leaders from government, academia, professional societies, device manufacturing, and pharmaceutical industries convened for 2 think tank meetings. Titled TREAT I and II, these forums examined approaches to improve the overall safety of PCI by optimizing strategies for antithrombotic drug use and radial artery access. This article summarizes the content and proceedings of these sessions.

01 marzo 2013

AMERICAN HEART JOURNAL. Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention

Cynthia M. Westerhout, PhD, Karen S. Pieper, MS, Stefan K. James, MD, PhD, Kenneth W. Mahaffey, MD, Frans Van de Werf, MD, PhD, Robert M. Califf, MD, MACC, Christopher B. Granger, MD, Paul W. Armstrong, MD

Aims: Dynamic risk models update the risk profile of ST-elevation myocardial infarction (STEMI) patients over the acute period following the event and have implications to clinical practice and research.

01 marzo 2013

AMERICAN HEART JOURNAL. Risk stratification in patients with unstable angina using absolute serial changes of 3 high-sensitive troponin assays

Tobias Reichlin, MD, Raphael Twerenbold, MD, Claudia Maushart, MD, Miriam Reiter, MD, Berit Moehring, MD, Nora Schaub, MD, Cathrin Balmelli, MD, Maria Rubini Gimenez, MD, Rebeca Hoeller, MD, Konstantin Sakarikos, MD, Beatrice Drexler, MD, Philip Haaf, MD, Stefan Osswald, MD, Christian Mueller, MD, FESC

Background: It is unknown whether unstable angina (UA) results in previously nondetectable low-level myocardial necrosis. We compared the pattern of myocardial necrosis between patients with UA, acute myocardial infarction (AMI), and noncardiac chest pain (NCCP) using 3 high-sensitive cardiac troponin (hs-cTn) assays.

01 marzo 2013

AMERICAN HEART JOURNAL. Incidence of heart failure and mortality after acute coronary syndromes

Padma Kaul, PhD, Justin A. Ezekowitz, MD, Paul W. Armstrong, MD, Becky K. Leung, Bsc, Anamaria Savu, PhD, Robert C. Welsh, MD, Hude Quan, MD, PhD, Merril L. Knudtson, MD, Finlay A. McAlister, MD

Background: The long-term incidence of heart failure (HF) in ST-elevation myocardial infarction (STEMI), non–ST-elevation myocardial infarction (NSTEMI), or unstable angina (UA) patients is uncertain. We examined the 1-year incidence of HF and its association with mortality among patients surviving their first acute coronary syndrome (ACS) hospitalization.

01 marzo 2014

AMERICAN HEART JOURNAL. Design and rationale of the TOTAL trial: A randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI

Sanjit S. Jolly, MD, MSc, John Cairns, MD, Salim Yusuf, MBBS, DPhil, Brandi Meeks, MEng, Olga Shestakovska, MSc, Lehana Thabane, PhD, Kari Niemelä, MD, PhD, Philippe Gabriel Steg, MD, Olivier F. Bertrand, MD, PhD, Sunil V. Rao, MD, Alvaro Avezum, MD, PhD, Warren J. Cantor, MD, Samir B. Pancholy, MD, Raul Moreno, MD, PhD, Anthony Gershlick, MBBS, Ravinay Bhindi, MBBS, PhD, Robert C. Welsh, MD, Asim N. Cheema, MD, PhD, Shahar Lavi, MD, Michael Rokoss, MD, Vladimír Džavík, MD

Background: A major limitation of primary percutaneous coronary intervention (PPCI) for the treatment of ST-elevation myocardial infarction (STEMI) is impaired microvascular perfusion due to embolization and obstruction of microcirculation with thrombus. Manual thrombectomy has the potential to reduce distal embolization and improve microvascular perfusion. Clinical trials have shown mixed results regarding thrombectomy.

01 marzo 2013

RADIOLOGY. Obstructive Coronary Artery Disease: Reverse Attenuation Gradient Sign at CT Indicates Distal Retrograde Flow—A Useful Sign for Differentiating Chronic Total Occlusion from Subtotal Occlusion

Minghua Li, MD, , Jiayin Zhang, MD, , Jingwei Pan, MD, and , Zhigang Lu, MD

Introduction: Chronic total occlusions (CTOs) and subtotal occlusions (SOs) are encountered frequently in patients with obstructive coronary artery disease referred for invasive coronary angiography (ICA) (1). The differentiation between these two entities is clinically important because CTOs usually involve a worse prognosis and more technical difficulties in recanalization (2–6). Both CTOs and SOs may appear as complete interruption of contrast medium–enhanced lumen at coronary computed tomographic (CT) angiography, which makes the differentiation difficult (7,8).

01 noviembre 2013

THE AMERICAN JOURNAL OF CARDIOLOGY. Therapeutic Management Changes and Mortality Rates over 30 Years in Ventricular Septal Rupture Complicating Acute Myocardial Infarction

Sophie Morillon-Lutun, MD, Delphine Maucort-Boulch, MD, PhD, Nathan Mewton, MD, PhD, Fadi Farhat, MD, PhD, Didier Bresson, MD, MSc, Nicolas Girerd, MD, MSc, Olivier Desebbe, MD, Roland Henaine, MD, PhD, Gilbert Kirkorian, MD, Eric Bonnefoy-Cudraz, MD, PhD

Recent studies have shown that the decrease in ventricular septal rupture (VSR) incidence after acute myocardial infarction is related to the improvement of reperfusion strategies. Our main objective was to explore the influence of therapeutic management changes on post-infarct VSR patient outcomes in a single reference center over a period of 30 years. We analyzed therapeutic management strategies and mortality rates in 228 patients with VSR after acute myocardial infarction admitted from 1981 to 2010. Patients were classified in 3 successive decades. There were no significant differences in clinical characteristics of patients with VSR at admission among those decades. Overall, surgery was performed in 159 patients (71.9%), primary transcatheter VSR closure was attempted in 5 patients (2.2%), and 64 patients (27.6%) were managed medically. Independent predictors of in-hospital mortality were VSR surgical repair (odds ratio [OR] 0.22, 95% confidence interval [CI] 0.1 to 0.7, p = 0.008), cardiogenic shock (OR 6.06, 95% CI 2.8 to 13.1, p <0.0001), and Killip class on admission (OR 1.75, 95% CI 1.1 to 9.9, p = 0.02). We found a significant 1-year mortality reduction between the first and second decades (hazard ratio 0.48, 95% CI 0.28 to 0.80; p = 0.005), with no significant change in the last decade (p = 0.2). This change was related to a systematic referral to surgical repair and shorter delays to VSR surgery (5.2 ± 6.3 vs 1.9 ± 3.2 days from first to second decade; p = 0.012). In conclusion, surgical repair remains the only significant efficient therapy to reduce mortality in patients with VSR (p <10−3). In-hospital prognosis remains disappointing. This contrasts with the favorable long-term outcome of patients who survive the perioperative period and are discharged from hospital.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.